Ototoxicity has been we ll described for many yea rs, but for most of that time, its mechani sm has been uncl ear. However, new studi es are finall y beginning to clari fy the mechan ism , and we now have at least a fairly good idea as to how ototoxicity occ urs in respo nse to aminog lycosi de therapy.
tal ev idence that shows that aminog lycosi des can interact fairly effic iently with transition metals, including iron and copp er, which can form free radicals.v' Aminog lycos ides also have a very high affinity for bindi ng to vario us types of phos phate lipids, and this affinity correlates fairly well with their pote ntia l ototoxicity. In effect, aminog lycosides are binding iron orcoppermolecules into act ive complexes and forming radical oxygen species that ca use ototoxicity.>'
A number of antioxida nt enzymes appear to reduce ototoxici ty-in duced hearing loss, w hich would appear to confirm the free-radical model of inj ury. One of the things we know about free radica ls is that regardless of how they are form ed, the type of inj ury they ca use confor ms to histologic findings see n in aminog lycosi deinjured coc hleae . "
Genetics of aminoglycoside ototoxicity
Fisc hel-Ghodsian et al discovered that aminog lycos ide ototoxic ity occ urred in multiple me mbers ofso me families and that the gene was passed only by the mothers, not the fathers. " Th ey believed that the tran smi ssion was probably mit ochond rial in origin. Indeed , they were the first to recognize a spec ific mutation associated with a high susce ptibly to aminog lycosi de ototox icity. They found a subst itution in adeni ne binding at posi tio n 1555 in the 12S subunit of mitochondrial RNA in a Chinese family; this gene was not found in 278 con tro ls. It is interesting that this is the same portion of that stra nd of nucleic acid that is involved in conferri ng resistance to aminoglycosides in yeast. Therefore, it appears that this is the portion of the nucleic acid sequence that is responsible for determining sensitivity orresistance to aminog lycosides . (Subsequently, Fisch el-Gh odsian identified another susceptibility mut ation in the mit ochond rial 12S ribosom al RNA gene delta T961Cn. 7 This defect is much less com mon than the defect at position 1555.)
Phenotypically, there is a difference in the way this gene is expressed in Asian popu lations and in Caucasian popu lations. In Chinese pat ients wit h this defect , hearing loss ca used by aminog lycos ide-induced ototoxicity is usually rapid and severe. Among whi tes in the United States, hearing loss tend s to be less severe and slow ly pro gressive, sometimes occurring over a period of yea rs after aminoglycoside administration. It has been speculated that the difference between these two populations may be attributable to another genetic mutation-either in the mitochondrial gene or possibly in the nuclear gene-that modulates or modifies the severity of the defect.
Virtually no one with a genetically mediated, aminoglycoside-induced hearing loss has a vestibular loss . It is fairly clear that patients who experience ototoxicity-induced hearing loss as a result of aminoglycoside administration have a genetic defect. Among those who do not have such a defect, the hearing loss appears to be a dose-related phenomenon.
What this means clinically is that a good history might allow us to prevent ototoxicity in some cases. Ifyou determine that a patient's first-degree relative has experienced an aminoglycoside-induced hearing loss, this is a clear suggestion that perhaps the patient should not receive an aminoglycoside.
Discussion
Dr. Rutka: Some evidence indicates that there might be a simple way to prevent aminoglycoside toxicity, especially from the basic science research concerning the prevention of oxygen and nitrogen radical species." One aspirin a day might be all that is necessary.
Dr. Coates: Yes, Schacht has published data on guinea pigs that show that salicylates protect hearing during the administration of gentamicin. 8 And others have indicated that aspirin protects against cisplatin ototoxicity." Dr. Roland: Therapeutic doses of aspirin might protect patients from aminoglycoside-induced hearing loss, but the data implicating high-dose salicylates in hearing loss are pretty solid .
Dr. Ovesen: Several study groups have identified a very specific receptor that mediates aminoglycoside toxicity in both the kidney and inner ear. It's called mega/in . It's found in the cytoplasm of at least some kidney cells , but we don't know which cells in the inner ear harbor it. Some researchers have reported that megalin resides in the outer hair cells , but others have not been able to confirm this.'?In our preliminary studies, we have localized megalin to the vascular stria ofthe cochlear duct. There may be a paracrine pathway at work, which could explain the few days' delay before changes in the outer hair cells are registered.
In Denmark we are working with an antagonist recently developed by a research group at the Institute of Medical Biochemistry at Aarhus University. We are conducting animal studies in which we combine the antagonist with gentamicin; by measuring otoacoustic emissions and performing brainstem audiometry and cochleography, we are attempting to determine whether the antagonist protects 16' Volume 83 • Suppl 4 against ototoxicity. Microscopic changes are observed in the outer hair cells but, surprisingly, the animals do not become deaf, as determined by cochleography. Ofcourse, these results have to be repeated, but it may create a problem with respect to our understanding of these animal models because we can always achieve some changes in the hair cells. But these changes may not give rise to a functional change in the hearing level. We have to put some fixation material into the inner ear, which we can do in two ways-either systemically or via direct injection through the round window membrane.The injection route, however, places a great deal of mechanical stress on the hairs , and they disappear immediately. So it is better to deliver the fixation material systemically.
Dr. Rutka: I'd like to make just a quick comment on ciprofloxacin toxicity. Over a period of 2 or 3 years recently, Health and Welfare Canada received reports of 5 cases of deafness or decreased hearing that had occurred in patients who took systemic ciprofloxacin. Four of these patients had taken I gram/day orally and the other had received 800 mg/day intravenously. Of this group, 2 patients recovered completely and I continued to have partial tonal deafness; the outcomes of the other 2 patients were unknown. The government became concerned because if systemic ciprofloxacin can cause hearing loss, we have to wonder if topical ciprofloxacin delivered to the middle ear might do the same thing.
Through the Freedom of Information Act in Canada, I was able to obtain pertinent information on the patients who were involved. One thing that I found very interesting is that none of these patients had ever had an audiogram. Therefore, we don 't know what their hearing was like before they took the ciprofloxacin. Moreover, 2 of these patients were documented to have taken other drugs that we know are ototoxic, and it is possible that the others might have taken an ototoxic drug, as well. Also , some of the se patients had only a unilateral hearing loss, which is very unlikely to be caused by a systemic medication. These are the kinds of data that we need to know before we start raising alarms.
Another compelling bit of information is that since oral ciprofloxacin was introduced into Canada, approximately 2 I million prescriptions have been written forthis medication . Therefore, if only a handful of patients experienced hearing loss, it is highly unlikely that it was caused by this medication.
